A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-19.1
The benefits of new combination vaccines are numerous – fewer injections mean simplified vaccination schedules, reduced pressure on health care systems, and less disruption to people receiving vaccines, with the additional potential benefit of boosting vaccine uptake.
However, for any new combination vaccine to be adopted, public health decision makers rely on health technology assessments (HTAs) to systematically assess the impact of introducing a new health technology from a multidisciplinary perspective. As part of an HTA, the costs and benefits (cost-effectiveness) of introducing a novel health technology must be assessed in relation to existing health technologies in use.
The costs of a novel health technology can be divided into a number of categories which include medical costs (e.g., the cost of a vaccine, and its storage and delivery), non-medical costs (e.g., transportation costs for the patient to and from a healthcare facility) and other costs such as productivity losses due to illness.
Because infectious disease spreads from person to person, vaccines provide both direct and indirect protection to the population at large. Individuals who receive a vaccine benefit from direct protection against disease, whilst the consequential reduction in the spread of disease confers indirect protection to the entire population. These indirect effects increase as more of the population is vaccinated and can be particularly important for infectious diseases that circulate at significant levels such as influenza and COVID-19.
To account for these indirect effects within traditional cost-effectiveness analyses, disease transmission models are used to understand how different levels of vaccine coverage impact the amount of disease spreading within a population. In the case of a combination vaccine targeting both influenza and COVID-19, such a transmission model must consider the impact of the vaccine on the circulation of both pathogens being targeted in the vaccine.
Although the benefits of introducing combination vaccines may seem clear, it is important for both public health overall, and for maintaining the social contract between populations and public health decision makers, that evidence-based decisions are made which consider direct and indirect effects, take a multidisciplinary approach, and adequately capturing any uncertainty.
The consequences of not capturing indirect effects can lead to health technologies or interventions being misvalued, resulting in poor decision making. In the past this has had catastrophic consequences – a failure to properly account for the relationship between the probability of infection and the mean age of first infection with rubella had significant health outcomes, leading to increases in congenital disease in Greece in 1993.2
At ICON Health Economics & Epidemiology, we have a broad range of expertise in infectious disease modelling. We model the clinical impact of a health technology or public health intervention like a vaccine, ensuring direct and indirect effects are considered, and use this as the basis for an economic evaluation. Stepping back to the broader economic perspective means we work in concert with other Health Economics & Epidemiology colleagues with expertise in evidence synthesis, cost-effectiveness analysis, and budget impact, to provide a comprehensive evaluation of the value of any new health technology.
To learn more about infectious disease modelling and vaccine commercialisation, please contact us.
References
1 Two-in-one flu and Covid jab passes advanced trial, BBC News, 10 June 2024 https://www.bbc.com/news/articles/ck55l4rk8z1o
2 Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review, BMJ, 04 December 1999 https://www.bmj.com/content/319/7223/1462.long
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel